| Zacks Company Profile for Zevra Therapeutics, Inc. (ZVRA : NSDQ) |
|
|
| |
| • Company Description |
| Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.
Number of Employees: 59 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $12.02 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 920,094 shares |
| Shares Outstanding: 54.68 (millions) |
| Market Capitalization: $657.25 (millions) |
| Beta: 1.97 |
| 52 Week High: $12.55 |
| 52 Week Low: $5.45 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
28.28% |
23.48% |
| 12 Week |
68.11% |
41.40% |
| Year To Date |
44.12% |
34.97% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1180 CELEBRATION BOULEVARD SUITE 103
-
CELEBRATION,FL 34747
USA |
ph: 321-939-3416
fax: 319-665-2577 |
nochsner@zevra.com |
https://zevra.com |
|
|
| |
| • General Corporate Information |
Officers
Neil F. McFarlane - President and Chief Executive Officer
R. LaDuane Clifton - Chief Financial Officer and Treasurer
Timothy J. Sangiovanni - Senior Vice President; Finance and Corporate Contr
Thomas D. Anderson - Director
John B. Bode - Director
|
|
Peer Information
Zevra Therapeutics, Inc. (GSAC)
Zevra Therapeutics, Inc. (CASI)
Zevra Therapeutics, Inc. (ALCD.)
Zevra Therapeutics, Inc. (OMNN)
Zevra Therapeutics, Inc. (CGPI.)
Zevra Therapeutics, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 488445206
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 54.68
Most Recent Split Date: 12.00 (0.06:1)
Beta: 1.97
Market Capitalization: $657.25 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.06 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.32 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
